期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

转化生长因子β_1及其受体在非酒精性脂肪肝组织中表达的临床意义 被引量：4

Study of the value of the expression of transforming growth factor β_1(TGF-β_1) and its receptor(TGF-β_1R) in non-alcoholic fatty liver disease
暂未订购
导出
摘要 目的研究转化生长因子β1(TGF-β1)及其受体(PDGFR)在非酒精性脂肪肝病(NAFLD)患者肝组织中的表达、分布和意义。方法用S-P免疫组织化学方法和原位杂交检测3种NAFLD组织中TGF-β1以及TGF-β1R的表达、分布情况,并进行定量分析。结果在NAFL各种病变肝组织中,TGF-β1以及TGF-β1R的表达变化随NAFL进行性演变而呈逐渐增强趋势,表达强度与分布基本一致。主要分布于肝实质细胞及附近的汇管区、纤维间隔、炎性反应细胞浸润聚集区。肝实质细胞强于其他间质和细胞。结论TGF-β1及其受体在非酒精性脂肪性肝炎(NASH)向NASH相关肝硬化的演变过程中,其表达活性不断增强,对病变的发生和进展起着及其重要的作用,可以作为评价疾病严重程度的指标。 Objective To study the expression and clinic value of transforming growth factor 61（TGF-β1） and its receptor （TGF-β1R） in non-aleoholic fatty liver disease（NAFLD）. Methods The expression of TGF-β1 and TGF- β1 R in three subgroup of NAFLD was analyzed by means of the immunohistochemistry （S-P） and in-situ hybridization. Results As the NAFLD developed, the expression of TGF-β1 and TGF-β1R were gradually increasing. The TGF-β1 and TGF-β1 R seem to appear simultaneously,which mainly distributed in hepatic cells and the region of the fibrosis and inflammation. The expression was stronger in hepatic cells than that of the other tissues or cells. Conclusion TGF-β1 and TGF-β1 R play a key role in the development of NAFLD. The TGF-β1 and TGF-β1 could be suitable to assess the severity of NAFLD.
作者 沈毅 罗春梅
机构地区 重庆医科大学附属第二医院内科 重庆市中医院基础部
出处 《检验医学与临床》 CAS 2009年第17期1431-1432,F0003,共3页 Laboratory Medicine and Clinic
关键词 非酒精性脂肪肝病 转化生长因子β1 转化生长因子Β1受体 NAFLD TGF-β1 TGF-β1 R
分类号 R575.5 [医药卫生—消化系统]
  • 相关文献

参考文献4

二级参考文献45

  • 1张立煌,方海林,裘云庆,姚航平,李敏伟,刘克洲.病毒性肝炎患者血清TGF－β1活性及其与肝纤维化关系的研究[J].胃肠病学和肝病学杂志,1996,5(4):298-301. 被引量：1
  • 2Aki Hanyu,Yasuhiro Ishidou,Takanori Ebisawa.The N domain of Smad7 is essential for specific inhibition of transforming growth factor-βsignaling[J].J Cell Bio,2001,155:1017-1027.
  • 3Inagaki Y,Mamura M,Kanamaru Y et al.Constitutive phosphorylation and nuclear localization of Smad3 are correlated with increased collagen gene transcription in activated hepatic stellate cells [ J ].J Cell Physiol,2001,87:117-123.
  • 4Shigeki Tsukada,John K.Westwick,Kenichi Ikejima,et al.SMAD and p38 MAPK signaling pathways independently regulate α1 collagen gene expressing in unstimulate and TGF-β stimulated hepatic stellate cells[J].J Biol Chem,2005,280:10055-10064.
  • 5Qi Cao,Ki M.Mak,Charles S.Lieber.DLPC decreases TGF-β 1-induced collagen mRNA by inhibiting p38 MAPK in hepatic stellate cells[J].Am J Physiol Gastrointest Liver Physiol,2002,283:1051-1061.
  • 6Carmen G.Lechuga,Zamira H.Hernández-Nazara,José-Alfredo Domínguez Rosales,et al.TGF-β1 modulates matrix metalloproteinase-13 expression in hepatic stellate cells by complex mechanisms involving p38MAPK,PI3-kinase,AKT,and p70S6K[J].Am J Physiol Gastrointest Liver Physiol,2004,287:974.
  • 7Wataru Wada,Hiroyuki Kuwano,Yoshihisa Hasegawa et al.The dependence of transforming growth factor-β-Induced collagen production on autocrine factor activin a in hepatic stellate cells [ J ].Endocrinology,2004,145:2753-59.
  • 8Rong Shao,Zengdun Shi,Philip J.Gotwals,et al.Cell and molecular regulation of Endothelin-1 production during hepatic wound healing[M].Cell Biol,2003,14:2327-41.
  • 9Elisadetta del Re,Jodie L.Babitt,Alnoor Pirani,et al.In the Absence of Type Ⅲ Receptor,the transforming growth factor (TGF)-β type Ⅱ-β Receptor requires the type Ⅰ Receptor to bind TGF-β2[J].Biol Chem,2004,279:22765-772.
  • 10K.L.Stenvers,M.L.Tursky,K.W.Harder,et al.Heart and liver defects and reduced transforming growth factor β2 sensitivity in transforming growth factor β Type Ⅲ receptor-deficient embryos[M].Cell Biol,2003,23:4371-85.

共引文献53

同被引文献44

  • 1中华医学会肝脏病学分会脂肪肝和酒精性肝病学组.非酒精性脂肪性肝病诊疗指南[J].中国肝脏病杂志（电子版）,2010,2(4):43-48. 被引量：484
  • 2孙丹莉,张予蜀,张振玉,袁捷,王书奎.非酒精性脂肪性肝病患者血清转化生长因子-β1与血脂和肝脏酶学变化的临床意义[J].中华消化杂志,2006,26(5):348-349. 被引量：7
  • 3Tessari P, Coracina A, Cosma A, et al. Hepatic lipid metabolism and non-alcoholic fatty liver disease [J]. Nutr Metab Cardiovasc Dis, 2009, 19(4): 291-302.
  • 4Suzuki D, Toyoda M, Kimura M, et al. Effects of Liraglutide, a human glucagon-like peptide-1 analogue, on body weight, body Fat area and body fat-related markers in patients with type 2 diabetes mellitus[J]. Intern Med, 2013, 52(10): 1029-34.
  • 5Li L, Miao Z, Liu R, et al. Liraglutide prevents hypoadipo- nectinemia-induced insulin resistance and alterations of gene expression involved in glucose and lipid metabolism[J]. Mol Med, 2011, 17(11-12): 1168-78.
  • 6Wajcberg E, Amarah A. Liraglutide in the management of type 2 diabetes[J]. Drug Des Devel Ther, 2010, 4: 279-90.
  • 7Burmeister M A, Ferre T, Ayala J E, et al. Acute activation of central GLP-1 receptors enhances hepatic insulin action and insulin secretion in high-fat-fed, insulin resistant mice [J]. Am J Physiol Endocrinol Metab, 2012, 302(3): E334-43.
  • 8Trevaskis JL, Griffin PS, Wittmer C, et al. Glucagon-like peptide-1 receptor agonism improves metabolic, biochemical, and histopathological indices of nonalcoholic steatohepatitis in mice [ J]. Am J Physiol Gastrointest Liver Physiol, 2012, 302(8): G762-72.
  • 9Marra F, Gastaldelli A, Svegliati BG, et al. Molecular basis and mechanisms of progression of non-alcoholic steatohepatitis [J]. Trends Mol Med, 2008, 14 (2): 72-81.
  • 10Nanck M, Frid A, Hermansen K, et al. Long-term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2-year results from the LEAD-2 study[J]. Diabetes Obes Metab, 2013, 15(3): 204-12.

引证文献4

二级引证文献45

检验医学与临床
2009年 第17期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部